Farnesoid X receptor directly regulates xenobiotic detoxification genes in the long-lived Little mice

Mechanisms of Ageing and Development

Volumn 134, Issue 9, 2013, Pages 407-415

  Jiang, Yanjun ^a   Jin, Jingling ^a   Iakova, Polina ^a   Hernandez, Julio Cesar ^a   Jawanmardi, Nicole ^a   Sullivan, Emily ^a   Guo, Grace L ^b   Timchenko, Nikolai A ^a   Darlington, Gretchen J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

FXR; Growth hormone; Little mice; Xenobiotic detoxification gene

Indexed keywords

FARNESOID X RECEPTOR; GLUTATHIONE TRANSFERASE A2; GROWTH HORMONE; MESSENGER RNA; RETINOID X RECEPTOR ALPHA;

ABCB1A GENE; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; FEMALE; FMO3 GENE; GENE; GENE EXPRESSION; GENETIC REGULATION; GSTA2 GENE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; TRANSACTIVATION; UPREGULATION; XENOBIOTIC METABOLISM;

MUS;

CDCA; CHENODEOXYCHOLIC ACID; CHIP; CHROMATIN IMMUNOPRECIPITATION ASSAY; DIMETHYL SULFOXIDE; DIRECT REPEAT; DMSO; DR; ELECTROPHORESIS MOBILITY SHIFT ASSAY; EMSA; ER; EVERTED REPEAT; FARNESOID X RECEPTOR; FXR; FXR RESPONSE ELEMENTS; FXRES; GH; GHRHR; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE RECEPTOR; IGF; INSULIN-LIKE GROWTH FACTOR; INVERTED REPEAT; IR; LITTLE MICE; PCR; POLYMERASE-CHAIN REACTION; RETINOID X RECEPTOR; RXR; TRANSCRIPTIONAL START SITE; TSS; XENOBIOTIC DETOXIFICATION GENE;

ANIMALS; BASE SEQUENCE; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; DIMERIZATION; FEMALE; GENE EXPRESSION REGULATION; GLUTATHIONE TRANSFERASE; GROWTH HORMONE; ISOENZYMES; LONGEVITY; MALE; MICE; MICE, MUTANT STRAINS; MOLECULAR SEQUENCE DATA; P-GLYCOPROTEINS; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; RETINOID X RECEPTOR ALPHA; TRANSCRIPTIONAL ACTIVATION; XENOBIOTICS;

EID: 84885852222     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2013.08.003     Document Type: Article

References (44)

1. Ananthanarayanan M., Li S., Balasubramaniyan N., Suchy F.J., Walsh M.J. Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1. J. Biol. Chem. 2004, 279:54348-54357.
2. Amador-Noguez D., Yagi K., Venable S., Darlington G. Gene expression profile of long-lived Ames dwarf mice and Little mice. Aging Cell 2004, 3(6):423-441.
3. Amador-Noguez D., Dean A., Huang W., Setchell K., Moore D., Darlington G. Alterations in xenobiotic metabolism in the long-lived Little mice. Aging Cell 2007, 6(4):453-470.
4. Bennett B.J., de Aguiar Vallim T.Q., Wang Z., Shih D.M., Meng Y., Gregory J., Allayee H., Lee R., Graham M., Crooke R., Edwards P.A., Hazen S.L., Lusis A.J. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013, 17(1):49-60.
5. Berryman D.E., Christiansen J.S., Johannsson G., Thorner M.O., Kopchick J.J. Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm. IGF Res. 2008, 18(6):455-471.
6. Calkin A.C., Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 2012, 13(4):213-224.
7. Chanda D., Park J.H., Choi H.S. Molecular basis of endocrine regulation by orphan nuclear receptor Small Heterodimer Partner. Endocr. J. 2008, 55(2):253-268.
8. Cui J., Huang L., Zhao A., Lew J.L., Yu J., Sahoo S., Meinke P.T., Royo I., Pelaez F., Wright S.D. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 2003, 278(12):10214-10220.
9. Deuschle U., Schüler J., Schulz A., Schlüter T., Kinzel O., Abel U., Kremoser C. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One 2012, 7(10):e43044.
10. Donahue L.R., Beamer W.G. Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. J. Endocrinol. 1993, 136(1):91-104.
11. Godfrey P., Rahal J.O., Beamer W.G., Copeland N.G., Jenkins N.A., Mayo K.E. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat. Genet. 1993, 4(3):227-232.
12. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., Galardi C., Wilson J.G., Lewis M.C., Roth M.E., Maloney P.R., Willson T.M., Kliewer S.A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell. 2000, 6(3):517-526.
13. Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., Wei M., Madia F., Cheng C.W., Hwang D., Martin-Montalvo A., Saavedra J., Ingles S., de Cabo R., Cohen P., Longo V.D. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 2011, 3(70):70ra13.
14. Iakova P., Timchenko L., Timchenko N.A. Intracellular signaling and hepatocellular carcinoma. Semin. Cancer Biol. 2011, 21:28-34.
15. Jiang Y., Iakova P., Jin J., Sullivan E., Sharin V., Hong I., Anakk S., Mayor A., Darlington G., Finegold M., Moore D., Timchenko T.A. FXR inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology 2013, 57(3):1098-1106.
16. Journe F., Durbecq V., Chaboteaux C., Rouas G., Laurent G., Nonclercq D., Sotiriou C., Body J.J., Larsimont D. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res. Treat. 2009, 115(3):523-535.
17. Kemper J.K. Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochim. Biophys. Acta 2011, 1812(8):842-850.
18. Koutsounas I., Giaginis C., Theocharis S. Farnesoid X Receptor (FXR) from normal to malignant state. Histol. Histopathol. 2012, 27(7):835-853.
19. Lew J.L., Zhao A., Yu J., Huang L., De Pedro N., Peláez F., Wright S.D., Cui J. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J. Biol. Chem. 2004, 279(10):8856-8861.
20. Li H., Chen F., Shang Q., Pan L., Shneider B.L., Chiang J.Y., Forman B.M., Ananthanarayanan M., Tint G.S., Salen G., Xu G. FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288(1):G60-G66.
21. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., Mangelsdorf D.J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell. 2000, 6(3):507-515.
22. McElwee J.J., Schuster E., Blanc E., Thomas J.H., Gems D. Shared transcriptional signature in Caenorhabditis elegans Dauer larvae and long-lived daf-2 mutants implicates detoxification system in longevity assurance. J. Biol. Chem. 2004, 279(43):44533-44543.
23. Miao J., Fang S., Lee J., Comstock C., Knudsen K.E., Kemper J.K. Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol. Cell. Biol. 2009, 29:6170-6181.
24. Modica S., Gadaleta R.M., Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal. 2010, 8:e005.
25. Ohno M., Kunimoto M., Nishizuka M., Osada S., Imagawa M. Ku proteins function as corepressors to regulate farnesoid X receptor-mediated gene expression. Biochem. Biophys. Res. Commun. 2009, 390:738-742.
26. Perez M.J., Gonzalez-Sanchez E., Gonzalez-Loyola A., Gonzalez-Buitrago J.M., Marin J.J. Mitochondrial genome depletion dysregulates bile acid- and paracetamol-induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells. Br. J. Pharmacol. 2011, 162(8):1686-1699.
27. Pineda Torra I., Freedman L.P., Garabedian M.J. Identification of DRIP205 as a coactivator for the Farnesoid X receptor. J. Biol. Chem. 2004, 279:36184-36191.
28. Pletcher S.D., Macdonald S.J., Marguerie R., Certa U., Stearns S.C., Goldstein D.B., Partridge L. Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr. Biol. 2002, 12(9):712-723.
29. Podvinec M., Kaufmann M.R., Handschin C., Meyer U.A. NUBIScan, an in silico approach for prediction of nuclear receptor response elements. Mol. Endocrinol. 2002, 16(6):1269-1279.
30. Rizzo G., Renga B., Antonelli E., Passeri D., Pellicciari R., Fiorucci S. The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol. Pharmacol. 2005, 68:551-558.
31. Sanyal S., Bavner A., Haroniti A., Nilsson L.M., Lundasen T., Rehnmark S., Witt M.R., Einarsson C., Talianidis I., Gustafsson J.A., Treuter E. Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:15665-15670.
32. Shore D.E., Carr C.E., Ruvkun G. Induction of cytoprotective pathways is central to the extension of lifespan conferred by multiple longevity pathways. PLoS Genet. 2012, 8(7):e1002792.
33. Steinbaugh M.J., Sun L.Y., Bartke A., Miller R.A. Activation of genes involved in xenobiotic metabolism is a shared signature of mouse models with extended lifespan. Am. J. Physiol. Endocrinol. Metab. 2012, 303(4):E488-E495.
34. Steuerman R., Shevah O., Laron Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur. J. Endocrinol. 2011, 164(4):485-489.
35. Swindell W.R. Gene expression profiling of long-lived dwarf mice: longevity-associated genes and relationships with diet, gender and aging. BMC Genom. 2007, 8:353.
36. Thomas A.M., Hart S.N., Kong B., Fang J., Zhong X.B., Guo G.L. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 2010, 51(4):1410-1419.
37. Unno A., Takada I., Takezawa S., Oishi H., Baba A., Shimizu T., Tokita A., Yanagisawa J., Kato S. TRRAP as a hepatic coactivator of LXR and FXR function. Biochem. Biophys. Res. Commun. 2005, 327:933-938.
38. Wang S., Lai K., Moy F.J., Bhat A., Hartman H.B., Evans M.J. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology 2006, 147(9):4025-4033.
39. Wang Y.D., Chen W.D., Moore D.D., Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008, 18(11):1087-1095.
40. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol. Pharmacol. 2009, 76(2):215-228.
41. Wu B., Ueno M., Kusaka T., Onodera M., Huang C.L., Hosomi N., Kanenishi K., Sakamoto H. Abcb1a and Abcb1b expression in senescence-accelerated mouse (SAM). Neurosci. Lett. 2009, 456(1):34-38.
42. Zhang Y., Castellani L.W., Sinal C.J., Gonzalez F.J., Edwards P.A. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 2004, 18:157-169.
43. Zhang Q., He F., Kuruba R., Gao X., Wilson A., Li J., Billiar T.R., Pitt B.R., Xie W., Li S. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc. Res. 2008, 77(3):560-569.
44. Xu G., Pan L.X., Li H., Forman B.M., Erickson S.K., Shefer S., Bollineni J., Batta A.K., Christie J., Wang T.H., Michel J., Yang S., Tsai R., Lai L., Shimada K., Tint G.S., Salen G. Regulation of the farnesoid X receptor (FXR) by bile acid flux in rabbits. J. Biol. Chem. 2002, 277(52):50491-50496.